StockData
Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc. (ASMB) stock

ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.50+1.21 (+5.68%)

Close on Nov 17, 2026Market cap $458.11MP/E –Yield –

Assembly Biosciences cash

Cash and short-term investments held at the end of each period.

Assembly Biosciences's cash was $320.40M at Jun 30, 2026. For fiscal 2025 it was $248.10M, up 121.4% from the year before. Over ten years it grew 13.9% a year on average. The highest annual figure on record is $274.04M in fiscal 2019.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$248.10M+121.4%
FY2024Dec 31, 2024$112.08M-13.9%
FY2023Dec 31, 2023$130.25M+42.2%
FY2022Dec 31, 2022$91.61M-37.5%
FY2021Dec 31, 2021$146.63M-32.2%
FY2020Dec 31, 2020$216.41M-21.0%
FY2019Dec 31, 2019$274.04M+25.7%
FY2018Dec 31, 2018$218.08M+81.8%
FY2017Dec 31, 2017$119.95M+126.5%
FY2016Dec 31, 2016$52.96M-21.7%
FY2015Dec 31, 2015$67.66M+132.6%
FY2014Dec 31, 2014$29.09M+7.5%
FY2013Dec 31, 2013$27.06M+32.1%
FY2012Dec 31, 2012$20.49M-44.6%
FY2011Dec 31, 2011$36.98M+153.8%
FY2010Dec 31, 2010$14.57M+17825.2%
FY2009Dec 31, 2009$81.29K+412.8%
FY2008Dec 31, 2008$15.85K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$320.40M+327.2%
Q1 FY2026Mar 31, 2026$226.60M+148.9%
Q4 FY2025Dec 31, 2025$248.10M+121.4%
Q3 FY2025Sep 30, 2025$232.60M+145.0%
Q2 FY2025Jun 30, 2025$75.00M-31.3%
Q1 FY2025Mar 31, 2025$91.03M-19.4%
Q4 FY2024Dec 31, 2024$112.08M-13.9%
Q3 FY2024Sep 30, 2024$94.95M+105.5%
Q2 FY2024Jun 30, 2024$109.22M+82.5%
Q1 FY2024Mar 31, 2024$112.98M+54.7%
Q4 FY2023Dec 31, 2023$130.25M+42.2%
Q3 FY2023Sep 30, 2023$46.21M-57.5%
Q2 FY2023Jun 30, 2023$59.83M-48.7%
Q1 FY2023Mar 31, 2023$73.02M-40.6%
Q4 FY2022Dec 31, 2022$91.61M-37.5%
Q3 FY2022Sep 30, 2022$108.65M-39.9%
Q2 FY2022Jun 30, 2022$116.69M-41.4%
Q1 FY2022Mar 31, 2022$123.00M-42.8%
Q4 FY2021Dec 31, 2021$146.63M-32.2%
Q3 FY2021Sep 30, 2021$180.90M-24.0%
Q2 FY2021Jun 30, 2021$199.08M-12.2%
Q1 FY2021Mar 31, 2021$214.88M-13.7%
Q4 FY2020Dec 31, 2020$216.41M-21.0%
Q3 FY2020Sep 30, 2020$237.94M+51.6%
Q2 FY2020Jun 30, 2020$226.71M+30.4%
Q1 FY2020Mar 31, 2020$249.13M+28.7%
Q4 FY2019Dec 31, 2019$274.04M+25.7%
Q3 FY2019Sep 30, 2019$156.94M-32.9%
Q2 FY2019Jun 30, 2019$173.81M+87.6%
Q1 FY2019Mar 31, 2019$193.54M+77.3%
Q4 FY2018Dec 31, 2018$218.08M+81.8%
Q3 FY2018Sep 30, 2018$233.94M+252.9%
Q2 FY2018Jun 30, 2018$92.67M+22.6%
Q1 FY2018Mar 31, 2018$109.16M+20.1%
Q4 FY2017Dec 31, 2017$119.95M+126.5%
Q3 FY2017Sep 30, 2017$66.30M+13.1%
Q2 FY2017Jun 30, 2017$75.58M–
Q1 FY2017Mar 31, 2017$90.92M–
Q4 FY2016Dec 31, 2016$52.96M–
Q3 FY2016Sep 30, 2016$58.65M–

More Assembly Biosciences figures

See a number that looks wrong?